Skip to main content
Erschienen in: AIDS and Behavior 1/2006

01.07.2006 | Original Paper

Disclosure of HIV Status and Adherence to Daily Drug Regimens Among HIV-infected Children in Uganda

verfasst von: Winnie Bikaako-Kajura, Emmanuel Luyirika, David W. Purcell, Julia Downing, Frank Kaharuza, Jonathan Mermin, Samuel Malamba, Rebecca Bunnell

Erschienen in: AIDS and Behavior | Sonderheft 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Pediatric adherence to daily drug regimens has not been widely assessed in Africa where majority of HIV infected children live. Using in-depth interviews of 42 HIV-infected children taking ART and/or cotrimoxazole prophylaxis, and 42 primary caregivers, at a comprehensive HIV/AIDS clinic in Uganda, we evaluated their adherence experiences for purposes of program improvement. Daily drug regimens provided by the pediatric clinic included cotrimoxazole prophylaxis as well as ART and cotrimoxazole combined. Complete disclosure of HIV status by caregivers to children and strong parental relationships were related to good adherence. Structural factors including poverty and stigma were barriers to adherence even for children who had had complete disclosure and a supportive relationship with a parent. To ensure adherence to life-extending medications, our findings underscore the need for providers to support caregivers to disclose, provide on-going support and maintain open communication with HIV-infected children taking cotrimoxazole prophylaxis and ART.
Literatur
Zurück zum Zitat African Network for the Care of Children Affected by AIDS (2004). Handbook on paediatric AIDS in Africa. African Network for the Care of Children Affected by AIDS (2004). Handbook on paediatric AIDS in Africa.
Zurück zum Zitat Belzer, M. E., Fuchs, D. N., Luftman, G. S., & Tucker, D. J. (1999). Antiretroviral adherence issues among HIV-positive adolescents and young adults. Journal of Adolescent Health, 25, 316–319.PubMedCrossRef Belzer, M. E., Fuchs, D. N., Luftman, G. S., & Tucker, D. J. (1999). Antiretroviral adherence issues among HIV-positive adolescents and young adults. Journal of Adolescent Health, 25, 316–319.PubMedCrossRef
Zurück zum Zitat Blasini, I., Chantry, C., Cruz, C., Ortiz, L., Salabarria, I., Scalley, N., & Matos, B. (2004). Disclosure model for pediatric patients living with HIV in Puerto Rico: Design, implementation, and evaluation. Journal of Developmental and Behavioral Pediatrics, 25, 181–189.PubMedCrossRef Blasini, I., Chantry, C., Cruz, C., Ortiz, L., Salabarria, I., Scalley, N., & Matos, B. (2004). Disclosure model for pediatric patients living with HIV in Puerto Rico: Design, implementation, and evaluation. Journal of Developmental and Behavioral Pediatrics, 25, 181–189.PubMedCrossRef
Zurück zum Zitat Boni, S., Pontali, E., De, G. P., Pedemonte, P., & Bassetti, D. (2000). Compliance to combination antiretroviral therapy in HIV-1 infected children. International Journal of Antimicrobial Agents, 16, 371–372.PubMedCrossRef Boni, S., Pontali, E., De, G. P., Pedemonte, P., & Bassetti, D. (2000). Compliance to combination antiretroviral therapy in HIV-1 infected children. International Journal of Antimicrobial Agents, 16, 371–372.PubMedCrossRef
Zurück zum Zitat Chintu, C., Bhat, G. J., Walker, A. S., Mulenga, V., Sinyinza, F., Lishimpi, K., & Farrelly, L. (2004). Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): A double-blind randomised placebo-controlled trial. Lancet, 364, 1865–1871.PubMedCrossRef Chintu, C., Bhat, G. J., Walker, A. S., Mulenga, V., Sinyinza, F., Lishimpi, K., & Farrelly, L. (2004). Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): A double-blind randomised placebo-controlled trial. Lancet, 364, 1865–1871.PubMedCrossRef
Zurück zum Zitat Elise, A., France, A. M., Louise, W. M., Bata, D., Francois, R., Roger, S., & Philippe, M. (2005). Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d’Ivoire. Journal of Acquired Immune Deficiency Syndromes, 40, 498–500.PubMedCrossRef Elise, A., France, A. M., Louise, W. M., Bata, D., Francois, R., Roger, S., & Philippe, M. (2005). Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d’Ivoire. Journal of Acquired Immune Deficiency Syndromes, 40, 498–500.PubMedCrossRef
Zurück zum Zitat Fassinou, P., Elenga, N., Rouet, F., Laguide, R., Kouakoussui, K. A., Timite, M., & Blanche, S. (2004). Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d’Ivoire. AIDS, 18, 1905–1913.PubMedCrossRef Fassinou, P., Elenga, N., Rouet, F., Laguide, R., Kouakoussui, K. A., Timite, M., & Blanche, S. (2004). Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d’Ivoire. AIDS, 18, 1905–1913.PubMedCrossRef
Zurück zum Zitat Lester, P., Chesney, M., Cooke, M., Whalley, P., Perez, B., Petru, A., & Dorenbaum, A. (2002). Diagnostic disclosure to HIV-infected children: How parents decide when and what to tell. Clinical Child Psychology and Psychiatry, 7, 85–99.CrossRef Lester, P., Chesney, M., Cooke, M., Whalley, P., Perez, B., Petru, A., & Dorenbaum, A. (2002). Diagnostic disclosure to HIV-infected children: How parents decide when and what to tell. Clinical Child Psychology and Psychiatry, 7, 85–99.CrossRef
Zurück zum Zitat Martinez, J., Bell, D., Camacho, R., Henry-Reid, L. M., Bell, M., Watson, C., & Rodriguez, F. (2000). Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic. Journal of the National Medical Association, 92, 55–61.PubMed Martinez, J., Bell, D., Camacho, R., Henry-Reid, L. M., Bell, M., Watson, C., & Rodriguez, F. (2000). Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic. Journal of the National Medical Association, 92, 55–61.PubMed
Zurück zum Zitat Mehta, S., Moore, R. D., & Graham, N. M. (1997). Potential factors affecting adherence with HIV therapy [editorial]. AIDS, 11, 1665–1670.PubMedCrossRef Mehta, S., Moore, R. D., & Graham, N. M. (1997). Potential factors affecting adherence with HIV therapy [editorial]. AIDS, 11, 1665–1670.PubMedCrossRef
Zurück zum Zitat Mermin, J., Lule, J., Ekwaru, J. P., Malamba, S., Downing, R., Ransom, R., & Kaharuza, F. (2004). Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and HIV viral load among persons with HIV in rural Uganda. Lancet, 364, 1428–1434.PubMedCrossRef Mermin, J., Lule, J., Ekwaru, J. P., Malamba, S., Downing, R., Ransom, R., & Kaharuza, F. (2004). Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and HIV viral load among persons with HIV in rural Uganda. Lancet, 364, 1428–1434.PubMedCrossRef
Zurück zum Zitat Murphy, D. A., Sarr, M., Durako, S. J., Moscicki, A. B., Wilson, C. M., & Muenz, L. R. (2003). Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Archives of Pediatric Adolescent Medicine, 157, 249–255.CrossRef Murphy, D. A., Sarr, M., Durako, S. J., Moscicki, A. B., Wilson, C. M., & Muenz, L. R. (2003). Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Archives of Pediatric Adolescent Medicine, 157, 249–255.CrossRef
Zurück zum Zitat Murphy, D. A., Wilson, C. M., Durako, S. J., Muenz, L. R., & Belzer, M. (2001). Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care, 13, 27–40.PubMedCrossRef Murphy, D. A., Wilson, C. M., Durako, S. J., Muenz, L. R., & Belzer, M. (2001). Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care, 13, 27–40.PubMedCrossRef
Zurück zum Zitat Reddington, C., Cohen, J., Baldillo, A., Toye, M., Smith, D., Kneut, C., & Demaria, A. (2000). Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatric Infectious Disease Journal, 19, 1148–1153.PubMedCrossRef Reddington, C., Cohen, J., Baldillo, A., Toye, M., Smith, D., Kneut, C., & Demaria, A. (2000). Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatric Infectious Disease Journal, 19, 1148–1153.PubMedCrossRef
Zurück zum Zitat Shingadia, D., Viani, R. M., Yogev, R., Binns, H., Dankner, W. M., Spector, S. A., & Chadwick, E. G. (2000). Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. Pediatrics, 105, E80.PubMedCrossRef Shingadia, D., Viani, R. M., Yogev, R., Binns, H., Dankner, W. M., Spector, S. A., & Chadwick, E. G. (2000). Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. Pediatrics, 105, E80.PubMedCrossRef
Zurück zum Zitat Steele, R. G., Anderson, B., Rindel, B., Dreyer, M. L., Perrin, K., Christensen, R., & Tyc, V. (2001). Adherence to antiretroviral therapy among HIV-positive children: Examination of the role of caregiver health beliefs. AIDS Care, 13, 617–629.PubMedCrossRef Steele, R. G., Anderson, B., Rindel, B., Dreyer, M. L., Perrin, K., Christensen, R., & Tyc, V. (2001). Adherence to antiretroviral therapy among HIV-positive children: Examination of the role of caregiver health beliefs. AIDS Care, 13, 617–629.PubMedCrossRef
Zurück zum Zitat Steele, R. G., & Grauer, D. (2003). Adherence to antiretroviral therapy for pediatric HIV infection: Review of the literature and recommendations for research. Clinical Child Family Psychology Review, 6, 17–30.CrossRef Steele, R. G., & Grauer, D. (2003). Adherence to antiretroviral therapy for pediatric HIV infection: Review of the literature and recommendations for research. Clinical Child Family Psychology Review, 6, 17–30.CrossRef
Zurück zum Zitat Temple, M. E., Koranyi, K. I., & Nahata, M. C. (2001). The safety and antiviral effect of protease inhibitors in children. Pharmacotherapy, 21, 287–294.PubMedCrossRef Temple, M. E., Koranyi, K. I., & Nahata, M. C. (2001). The safety and antiviral effect of protease inhibitors in children. Pharmacotherapy, 21, 287–294.PubMedCrossRef
Zurück zum Zitat UNAIDS. (2004). Report on the global HIV/AIDS epidemic: 4th global report. [Retrieved from: http://www.unaids.org/bangkok2004/GAR2004_pdf/UNAIDSGlobalReport2004_en.pdf]. UNAIDS. (2004). Report on the global HIV/AIDS epidemic: 4th global report. [Retrieved from: http://​www.​unaids.​org/​bangkok2004/​GAR2004_​pdf/​UNAIDSGlobalRepo​rt2004_​en.​pdf].
Zurück zum Zitat van Dyke, R. B., Lee, S., Johnson, G. M., Wiznia, A., Mohan, K., Stanley, K., & Morse, E. V. (2002). Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics, 109, 1–7.CrossRef van Dyke, R. B., Lee, S., Johnson, G. M., Wiznia, A., Mohan, K., Stanley, K., & Morse, E. V. (2002). Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics, 109, 1–7.CrossRef
Zurück zum Zitat van Rossum, A. M., Fraaij, P. L., & de Groot, R. (2002). Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infectious Disease, 2, 93–102.CrossRef van Rossum, A. M., Fraaij, P. L., & de Groot, R. (2002). Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infectious Disease, 2, 93–102.CrossRef
Zurück zum Zitat Watson, D. C., & Farley, J. J. (1999). Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatric Infectious Disease Journal, 18, 682–689.PubMedCrossRef Watson, D. C., & Farley, J. J. (1999). Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatric Infectious Disease Journal, 18, 682–689.PubMedCrossRef
Zurück zum Zitat Waugh, S. (2003). Parental views on disclosure of diagnosis to their HIV-positive children. AIDS Care, 15, 169–176.PubMedCrossRef Waugh, S. (2003). Parental views on disclosure of diagnosis to their HIV-positive children. AIDS Care, 15, 169–176.PubMedCrossRef
Zurück zum Zitat Williams A., & Friedland, G. (1997). Adherence, compliance, and HAART. AIDS Clinical Care, 9, 51–54, 58.PubMed Williams A., & Friedland, G. (1997). Adherence, compliance, and HAART. AIDS Clinical Care, 9, 51–54, 58.PubMed
Zurück zum Zitat World Health Organization. (2006). Who expert consultation on cotrimoxazole prophylaxis in HIV infection. [Retrieved from: http://www.womenchildrenhiv.org]. World Health Organization. (2006). Who expert consultation on cotrimoxazole prophylaxis in HIV infection. [Retrieved from: http://​www.​womenchildrenhiv​.​org].
Metadaten
Titel
Disclosure of HIV Status and Adherence to Daily Drug Regimens Among HIV-infected Children in Uganda
verfasst von
Winnie Bikaako-Kajura
Emmanuel Luyirika
David W. Purcell
Julia Downing
Frank Kaharuza
Jonathan Mermin
Samuel Malamba
Rebecca Bunnell
Publikationsdatum
01.07.2006
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe Sonderheft 1/2006
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-006-9141-3

Weitere Artikel der Sonderheft 1/2006

AIDS and Behavior 1/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.